Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms Al18F-PSMA-BCH |
Target |
Mechanism PSMA inhibitors(Prostate-specific membrane antigen inhibitors), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Phase 2 | CN | 20 Aug 2022 |
Not Applicable | - | - | (Al18F-PSMA-BCH) | sjrufxoenr(apxdcuommp) = 22 tumor lesions were increased, 4 of them were decreased and one remained between 1 h and 2 h p.i. jxhvvdtunr (lelhcfjcnj ) View more | - | 21 May 2019 |